Emerging Immunotherapy Targets in Early Drug Development
Morchón-Araujo, Daniel (Vall d'Hebron Institut d'Oncologia)
Catani, Greta (Vall d'Hebron Institut d'Oncologia)
Mirallas, Oriol (Vall d'Hebron Institut d'Oncologia)
Pretelli, Giulia (Vall d'Hebron Institut d'Oncologia)
Sánchez-Pérez, Vicky (Vall d'Hebron Institut d'Oncologia)
Vieito, María (Vall d'Hebron Institut d'Oncologia)
Braña, Irene (Vall d'Hebron Institut d'Oncologia)
Pujol-Borrell, Ricardo (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Garralda, Elena (Vall d'Hebron Institut d'Oncologia)
Hernando-Calvo, Alberto (Vall d'Hebron Institut d'Oncologia)

Date:	2025
Abstract:	Immunotherapy has significantly changed the treatment paradigm for solid tumors, with immune checkpoint inhibitors now established in the management of many malignancies. Despite initial success, durable responses remain limited to a subset of patients, often less than 30%, due to both intrinsic and acquired resistance mechanisms. These challenges have prompted the development of next-generation immunotherapies. Recent efforts have expanded the scope of immunotherapy beyond PD-1/PD-L1 and CTLA-4 inhibition, focusing on new immune targets currently under investigation in early phase clinical trials. These include novel immune checkpoint inhibitors, immunomodulators targeting the tumor microenvironment, and bispecific antibodies. This review provides a comprehensive overview of emerging immune targets currently being investigated in early drug development, discussing their mechanisms of action, preliminary clinical outcomes, and potential future directions.
Grants:	"la Caixa" Foundation LCF/PR/CE07/50610001
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Immunotherapy; ; Phase 1 trial ; Early drug development ; Checkpoint inhibitors ; Bispecific antibodies ; Tumor microenvironment
Published in:	International journal of molecular sciences, Vol. 26 Núm. 11 (june 2025) , p. 5394, ISSN 1422-0067

DOI: 10.3390/ijms26115394
PMID: 40508202

39 p, 1.5 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles